Breaking News Instant updates and real-time market news.

MRK

Merck

$63.83

1.055 (1.68%)

, BMY

Bristol-Myers

$50.48

-4.95 (-8.93%)

10:39
10/10/16
10/10
10:39
10/10/16
10:39

Bristol-Myers tumbles, levels to watch

The stock was last down over 9.6% to $50.07. At that price next support is at $49.34, which would be a fresh 52-week low. Resistance is at $50.85.

MRK

Merck

$63.83

1.055 (1.68%)

BMY

Bristol-Myers

$50.48

-4.95 (-8.93%)

  • 25

    Oct

  • 27

    Oct

  • 31

    Oct

  • 06

    Nov

MRK Merck
$63.83

1.055 (1.68%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
10/10/16
BMOC
10/10/16
NO CHANGE
BMOC
Merck should strengthen leadership in first line NSCLC, says BMO Capital
BMO Capital analyst Alex Arfaei says that upcoming data should strengthen Merck's (MRK) lead in 1L NSCLC. The analyst adds that the data could support off-label use of Merck's Keytruda in additional 1L NSCLC patients, and he says that the data "should be negative" for Bristol-Myers' (BMY) Opdivo drug. Arfaei keeps an Outperform rating on Merck and a Market Perform rating on Bristol-Myers.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Market Perform
Merck 'steals the show' at ESMO with Keytruda data, says Leerink
Leerink analyst Seamus Fernandez said Merck (MRK) stole the show at ESMO with its Keytruda data and he continues to think the company will dominate first line lung cancer treatment for years to come in patients with 50%+ PDL1 expression. Additionally, he expects Merck to gain additional traction in the overall market, noting that confirmation that Keytruda is benefiting patients when combined with Alimta/carboplatin with Alimta maintenance raises the possibility Merck could compete broadly in the overall non-squamous patient population. However, Fernandez keeps a Market Perform rating on Merck, as he thinks its current valuation largely reflects improved growth prospects through 2020.
10/10/16
JMPS
10/10/16
NO CHANGE
JMPS
Incyte treatment looking 'promising,' says JMP Securities
After reviewing recent data, JMP Securities analyst Liisa Bayko says that the combination of Incyte's (INCY) Epacadostat plus Merck's (MRK) Keytruda is "emerging as a promising treatment, potentially even best in class." The analyst says that the progression free survival rate of the combination in melanoma patients "is emerging to be quite competitive," while the efficacy rate in other solid tumors "seemed encouraging." The analyst raised her price target on Incyte to $110 from $100 and keeps an Outperform rating on the stock.
BMY Bristol-Myers
$50.48

-4.95 (-8.93%)

09/20/16
SBSH
09/20/16
NO CHANGE
Target $70
SBSH
Buy
Bristol-Myers price target lowered to $70 from $75 at Citi
In a research note titled "Brace Yourself. Attractive Valuation but No Near-Term Respite.," Citi analyst Andrew Baum lowered his price target for shares of Bristol-Myers Squibb to $70 from $75. The analyst lowered his earnings forecasts by up to 8% to reflect the "limited supportive data" in the non-small cell lung cancer indication. Baum keeps a Buy rating on the shares as he views the valuation as attractive. He points out, however, the near-term news-flow is likely to be negative.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.

TODAY'S FREE FLY STORIES

03:30
01/17/18
01/17
03:30
01/17/18
03:30
General news
FX Action: USD-CAD has maintained a consolidation »

FX Action: USD-CAD has…

02:45
01/17/18
01/17
02:45
01/17/18
02:45
General news
FX Update: The dollar staged a bounce after posting fresh lows »

FX Update: The dollar…

NUVA

NuVasive

$51.99

-1.34 (-2.51%)

20:43
01/16/18
01/16
20:43
01/16/18
20:43
Downgrade
NuVasive rating change at Wells Fargo »

NuVasive downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

20:38
01/16/18
01/16
20:38
01/16/18
20:38
Recommendations
Juno Therapeutics, Celgene, Acquired by GILD 9/17, Gilead analyst commentary at Citi »

Juno could be worth $110…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

KITE

Acquired by GILD 9/17

GILD

Gilead

$80.25

1.23 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 12

    Feb

  • 16

    Feb

  • 25

    Mar

SNP

Sinopec

$83.07

-1 (-1.19%)

20:35
01/16/18
01/16
20:35
01/16/18
20:35
Upgrade
Sinopec rating change at Jefferies »

Sinopec upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHLX

Shell Midstream

$30.74

0.21 (0.69%)

20:34
01/16/18
01/16
20:34
01/16/18
20:34
Downgrade
Shell Midstream rating change at Stifel »

Shell Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

UNH

UnitedHealth

$232.90

4.26 (1.86%)

20:31
01/16/18
01/16
20:31
01/16/18
20:31
Recommendations
UnitedHealth analyst commentary at Piper Jaffray »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

AVXS

AveXis

$105.01

-12.49 (-10.63%)

20:31
01/16/18
01/16
20:31
01/16/18
20:31
Syndicate
AveXis 3.921M share Secondary priced at $102.00 »

Goldman Sachs, Jefferies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

OZRK

Bank of the Ozarks

$52.23

-0.24 (-0.46%)

20:26
01/16/18
01/16
20:26
01/16/18
20:26
Downgrade
Bank of the Ozarks rating change at Keefe Bruyette »

Bank of the Ozarks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 30

    Jan

WP

Worldpay

$78.26

0.66 (0.85%)

, VNTV

Symbol changed to WP

20:25
01/16/18
01/16
20:25
01/16/18
20:25
Initiation
Worldpay, Symbol changed to WP initiated at Goldman Sachs »

Worldpay reinstated with…

WP

Worldpay

$78.26

0.66 (0.85%)

VNTV

Symbol changed to WP

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAC

Bank of America

$31.24

0.05 (0.16%)

, GS

Goldman Sachs

$258.46

1.43 (0.56%)

20:25
01/16/18
01/16
20:25
01/16/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

BAC

Bank of America

$31.24

0.05 (0.16%)

GS

Goldman Sachs

$258.46

1.43 (0.56%)

USB

U.S. Bancorp

$57.17

0.19 (0.33%)

FAST

Fastenal

$55.44

-0.15 (-0.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

  • 15

    Feb

C

Citi

$77.11

0.27 (0.35%)

20:20
01/16/18
01/16
20:20
01/16/18
20:20
Downgrade
Citi rating change at Keefe Bruyette »

Citi downgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 18

    Jan

  • 24

    Jan

O

Realty Income

$52.94

0.22 (0.42%)

19:12
01/16/18
01/16
19:12
01/16/18
19:12
Hot Stocks
Realty Income raises monthly dividend to 21.9c per share from 21.25c »

Realty Income announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:05
01/16/18
01/16
19:05
01/16/18
19:05
Hot Stocks
New Gold sees FY18 gold production 525,000-595,000 ounces »

Sees FY18 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:04
01/16/18
01/16
19:04
01/16/18
19:04
Hot Stocks
New Gold reports Q4 gold production 154,446 ounces »

Reports Q4 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGD

New Gold

$3.44

0.05 (1.47%)

19:04
01/16/18
01/16
19:04
01/16/18
19:04
Hot Stocks
New Gold reports FY17 gold production 430,864 ounces »

Reports FY17 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PYPL

PayPal

$80.42

-0.12 (-0.15%)

18:50
01/16/18
01/16
18:50
01/16/18
18:50
Earnings
PayPal sees FY18 revenue $15B-$15.25B, consensus $15.35B »

Backs FY18 TPV Growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

CE

Celanese

$109.67

-1.67 (-1.50%)

18:32
01/16/18
01/16
18:32
01/16/18
18:32
Hot Stocks
Celanese increases the price of low density polyethylene to 4c »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

RIG

Transocean

$11.47

-0.73 (-5.98%)

18:27
01/16/18
01/16
18:27
01/16/18
18:27
Hot Stocks
Transocean shareholders show 'overwhelming support' for Songa transaction »

Transocean announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

WMT

Walmart

$100.69

-0.18 (-0.18%)

18:13
01/16/18
01/16
18:13
01/16/18
18:13
Periodicals
Wal-Mart COO to be named international CEO, Reuters says »

Wal-Mart Stores COO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

CME

CME Group

$152.20

-0.53 (-0.35%)

18:05
01/16/18
01/16
18:05
01/16/18
18:05
Hot Stocks
CME reaches daily trading volume record for Henry Hub Nat Gas futures on Jan 12 »

CME Group announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 01

    Feb

CE

Celanese

$109.67

-1.67 (-1.50%)

18:02
01/16/18
01/16
18:02
01/16/18
18:02
Hot Stocks
Celanese announces price increases for engineered materials polymer products »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

SRC

Spirit Realty

$8.07

-0.03 (-0.37%)

17:46
01/16/18
01/16
17:46
01/16/18
17:46
Hot Stocks
Spirit Realty funds $35M into Shopko master lease »

Spirit Realty Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$36.01

-1.83 (-4.84%)

17:45
01/16/18
01/16
17:45
01/16/18
17:45
Conference/Events
Nutanix management to meet with Piper Jaffray »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

17:41
01/16/18
01/16
17:41
01/16/18
17:41
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Juno Therapeutics…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

NEWA

Newater Technology

$15.80

2.8 (21.54%)

VRS

Verso

$17.00

0.06 (0.35%)

EXEL

Exelixis

$29.65

-0.73 (-2.40%)

IPSEY

Ipsen

RNST

Renasant

$43.86

0.15 (0.34%)

IBKR

Interactive Brokers

$62.45

-0.65 (-1.03%)

CSX

CSX

$58.13

-1.12 (-1.89%)

ATEN

A10 Networks

$7.31

-0.27 (-3.56%)

HTGM

HTG Molecular

$3.50

-0.14 (-3.85%)

HIVE

Aerohive

$5.70

-0.19 (-3.23%)

OBLN

Obalon Therapeutics

$7.93

0.03 (0.38%)

XON

Intrexon

$13.77

-0.94 (-6.39%)

BOOT

Boot Barn

$19.10

-0.15 (-0.78%)

F

Ford

$13.10

-0.13 (-0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

  • 16

    Jan

  • 16

    Jan

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 08

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 26

    Feb

  • 01

    Mar

  • 25

    Mar

  • 17

    Jan

  • 18

    Jan

  • 19

    Jan

  • 19

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.